General discussion, page-19487

- income derived from Clarion (some numbers)............... Not until the first qtyly after patents have begin therapy. This could be 2nd quarter.
- a cap raise........................................Not at this level of liquidity. I would assume a major push in developments leading into a raising.

Next lot of news

Near term;
*Updated and the RePosa TP2B3 site approvals and accepting patents.
*Analytic report and TP2 PSIGAD
*Pre IND/FDA feed back on PSIGAD TP2B for the US
*Updates on CannQuit N trials
*Mr Robert Clark's package updates. Assume that this package will be re-negotiated.

*Possibly;
675A interim data. Early H2
Regulatory developments in Europe for the RePosa trials.
Regulatory developments in UK for PSIGAD trials.
CannQuit O. Bigger TAM than CannQuit N. (Having 4 trials might be a tall order with available COH)
Clarion updates and Qtrly. Late H2

Hopefully;
Once Analytic PSIGAD report, patent intake with Reposa TP2B3, CannQuit N updates and positive PSI TP2B FDA feedback a new and updated presentation squarely focused on the US market focusing on late stage drug developments and benchmarks. Commencing RePosa TP2B3 will be a huge milestone for Incannex bring IHL-42X our first drug/compound asset squarely into late stage development. A big tick for the US investors.

GL @Slyau90